Fuji Pharma Co., Ltd.
Notice Regarding Revision of Earnings Guidance
The cumulative net sales for the second quarter of the fiscal year ending September 2026 have been revised upward by 1.3% from the previous forecast to JPY 29,420 million, and operating income by 47.0% to JPY 4,100 million. Conversely, net income attributable to owners of parent has been revised downward by 55.4% to JPY 860 million due to the recording of a stock valuation loss.
Key Figures
- Second Quarter Net Sales: JPY 29,420 million (1.3% increase from previous forecast)
- Second Quarter Operating Income: JPY 4,100 million (47.0% increase from previous forecast)
- Stock Valuation Loss: JPY 2,457 million (valuation loss on Alvotech shares)
AI要約
Details of Earnings Guidance Revision
Fuji Pharmaceutical Industries Co., Ltd. has revised its earnings guidance for the cumulative second quarter period and full fiscal year ending September 2026. The cumulative second quarter net sales were revised upward to JPY 29,420 million (1.3% increase from the previous forecast), operating income to JPY 4,100 million (47.0% increase), and ordinary income to JPY 3,970 million (49.2% increase). Conversely, net income attributable to owners of parent for the quarter was revised downward to JPY 860 million (55.4% decrease). For the full year, net sales were revised upward to JPY 59,250 million (3.1% increase), operating income to JPY 6,120 million (10.9% increase), and ordinary income to JPY 5,880 million (12.2% increase), while net income was revised downward to JPY 2,240 million (41.2% decrease).
Reasons for Revision and Future Outlook
Due to stronger-than-expected sales of core products leading to improved profitability, forecasts for net sales, operating income, and ordinary income have been revised upward. Conversely, a stock valuation loss of JPY 2,457 million was recorded stemming from a significant decline in the share price of Alvotech Holding S.A., a Nasdaq-listed company, resulting in a downward revision of net income forecasts. The holding of Alvotech shares is part of the growth strategy for the biosimilar business, and collaboration with the company is being strengthened. There is no change to the dividend forecast.
